Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B. Staber(Vienna General Hospital), Claire Dearden(Royal Marsden Hospital), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Gregor Hoermann(University of Freiburg), Marco Herling(Unknown), Mar Bellido(University Medical Center Groningen), Francesco Zaja, Kimmo Porkka(Helsinki University Hospital), Olivier Tournilhac, Emmanuel Bachy(Université Claude Bernard Lyon 1), Ingrid Simonitsch‐Klupp(Medical University of Vienna), Andrei R. Shustov(Seattle Cancer Care Alliance), Matthew S. Davids(Dana-Farber Cancer Institute), Georg Hopfinger(Medical University of Vienna), Stefan Kubicek(Austrian Academy of Sciences), Eric Jacobsen(Dana-Farber Cancer Institute), Marius E. Mayerhoefer(NYU Langone Health), Ulrich Jaeger(Medical University of Vienna), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center)
Cited by 161
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k